SEC Form 4 · accession 0001114220-18-000037
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Greg Madison
Officer — President and CEO · Director
Period of report
Mar 20, 2018
Accepted (ET)
Mar 22, 2018 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 20, 2018 | A | 152,500 | $0.00 | A | 566,586 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $4.16 | Mar 20, 2018 | A | 305,000 | A | Mar 20, 2019 | Mar 20, 2028 | Common Stock | 305,000 | 305,000 | D |
Explanation of responses
- F1The 152,500 shares are restricted common stock, with one-third of the 152,500 shares vesting on March 20, 2019 and one-twelfth vesting on each of June 20, 2019, September 20, 2019, December 20, 2019, March 20, 2020, June 20, 2020, September 20, 2020, December 20, 2020 and March 20, 2021.
- F2Includes 303,747 shares of restricted stock.
- F3The stock options vest according to the following schedule: one-third of the 305,000 options will vest on March 20, 2019 and one-twelfth will vest on each of June 20, 2019, September 20, 2019, December 20, 2019, March 20, 2020, June 20, 2020, September 20, 2020, December 20, 2020 and March 20, 2021.
Remarks
Exhibit List - Exhibit 24 - Power of Attorney